Vaccines
Genventis is committed to advancing mRNA vaccines for the prevention and treatment of infectious diseases. Our mRNA vaccine technology we offers potential advantages in efficacy, speed of development, and production scalability and reliability, which have the potential to position us to better prepare for and respond to infectious disease threats that place millions of people at risk around the world.
Our interest in vaccines
We focus on uncovering new therapeutic targets and pathways across both common and rare immune‑mediated diseases. Some of the most frequently diagnosed immune challenge diseases include rheumatoid arthritis, psoriasis, type 1 diabetes, and lupus. NCBI +1 Our work bridges discovery research, translational science, and clinical development to bring promising therapies to patients more efficiently.
Exploring new modalities
Bringing precision medicine to vaccines
To meet the demands of complex immune disorders, we leverage advanced therapeutic modalities such as biologics, cell therapies, and precision‑targeted interventions. These novel approaches aim to bring durable responses and better long‑term outcomes where traditional treatments may fall short.
We’ve made significant investments over the past few year and hope to usher in a new era in immunology. We're pursuing biomarkers that could play a key role in identifying people who are more likely to respond to therapies. The ultimate goal is to be able to deliver the right medicine for the right patient at the right time.
A Unique Range of Vaccine Technologies
There are so many different disease-causing microbes that no single approach could tackle them all. Our vaccine development toolbox we enables us to target proteins, polysaccharides, and a wide range of other components that help pathogens thrive in the human body.
Learn more about our technologies
Our areas of focus
Vaccines play a critical and enduring role in global public health, helping to prevent a variety of infectious diseases and making some once-feared diseases, such as smallpox, a thing of the past. Yet, vaccine-preventable diseases and outbreaks persist in some contexts — due largely to low vaccination rates often resulting from vaccine hesitancy or challenges with access.
Our Approach to Vaccine Innovation
Messenger RNA (mRNA)
mRNA science has given our R&D teams more ways to develop vaccines against different infectious diseases1 and to keep pace with emerging health threats.
Artificial Intelligence (AI)
Since 2023, Genventis have collaborated with patient on a variety of blood and marrow disorders such as lymphoma, leukemia, multiple myeloma, aplastic anemia and sickle cell anemia. We possess specialized expertise in hematopoietic stem cell transplantation (HSCT), cellular therapy and gene therapy.
Beyond Infectious Disease
We have the opportunity to pave the way for next-generation vaccines, which could target not only infectious diseases, but non-infectious ones as well, like acne.
Related links
Vaccines
We’ve been discovering, developing, supplying and delivering vaccines to help prevent disease for over 130 years.
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
Our science-led strategy is key to delivering long-term value for patients, employees, and shareholders.